Luvometinib, a highly selective MEK inhibitor: fills a gap in the...

Luvometinib, a highly selective MEK inhibitor: fills a gap in the treatment of rare tumors with dual indications.

In the field of oncology targeted therapy, the development of precision drugs for specific gene abnormalities has always been a key direction for breaking through challenges and extending patient survival. DengyuePharma has discovered that Luvometinib (trade name: Fumaining®), an independently developed Class 1 innovative drug by Fosun Pharma, stands out in the treatment of MET gene...